Accurate, balanced evidence-based information about medicines
Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDFNPS RADAR November 2007 NPS RADAR November 2007
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR November 2007 NPS RADAR>Full Issue>Health Professional Publication | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Correspondence from Servier Laboratories on strontium ranelate NPS RADAR>Correspondence>Health Professional Publication | Correspondence between Servier Laboratories and NPS on use of strontium ranelate for postmenopausal osteoporosis. |
| Strontium ranelate (Protos) for postmenopausal osteoporosis NPS RADAR>Review>Health Professional Publication | Reviews use of strontium ranelate for postmenopausal osteoporosis, with emphasis on reducing risk of fracture. |
| Additional content — Strontium ranelate (Protos) for postmenopausal osteoporosis: Differences between trial populations used for indirect comparisons between strontium and alendronate NPS RADAR>Web Only Item>Health Professional Publication | Comparison of TROPOS, SOTI, FIT-1, and FIT-2 trial populations provided as additional content on strontium ranelate (Protos) for postmenopausal osteoporosis. |
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus NPS RADAR>Review>Health Professional Publication | Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure. |
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus — Intolerance and contraindications to metformin NPS RADAR>Web Only Item>Health Professional Publication | Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidodis, and renal impairment. |
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus --- New York Heart Association grading of heart failure (NYHA) NPS RADAR>Web Only Item>Health Professional Publication | Provides New York Heart Association grading of heart failure (NYHA) as additional content to rosiglitazone use for type 2 diabetes mellitus. |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2007-11-01 00:00:00
The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of clinical circumstances of each patient.
RSS feed
